A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Status Completed

Clinical Trial Summary

The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.

Clinical Trial Description

Epithelial ovarian cancer (EOC) is usually lethal unless it is diagnosed at an early stage, thus early detection is likely to play an important role in reducing its mortality. Within the Ovarian Specialized Programs of Research Excellence Pacific Ovarian Cancer Research Consortium (POCRC) researchers have been working for a decade to discover, develop, and validate biomarkers (proteins or substances found in blood) that could help save lives by detecting EOC early. During the last five years several biomarkers, including CA125, have been evaluated for their ability to detect EOC at an earlier stage. The best markers will now be studied in a new randomized controlled trial of ovarian cancer screening. ;

Study Design

Related Conditions & MeSH terms

Epithelial Ovarian Cancer
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms

Clinical Trial Details

NCT number	NCT01121640
Study type	Interventional
Source	Fred Hutchinson Cancer Research Center
Contact
Status	Completed
Phase	N/A
Start date	November 2009
Completion date	May 7, 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03393884` - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)	Phase 1/Phase 2
Recruiting	`NCT05200559` - T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04546373` - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting	`NCT03371693` - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer	Phase 3
Completed	`NCT01442051` - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer	N/A
Not yet recruiting	`NCT04983550` - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC	Phase 2
Completed	`NCT02480374` - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer	Phase 1
Recruiting	`NCT01680575` - Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer	N/A
Terminated	`NCT01202890` - Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer	Phase 1
Completed	`NCT00561795` - Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors	Phase 2
Completed	`NCT00314678` - Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer	Phase 2
Not yet recruiting	`NCT04889495` - A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Not yet recruiting	`NCT06010667` - A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Recruiting	`NCT06085456` - Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
Completed	`NCT06366997` - Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
Active, not recruiting	`NCT05212779` - Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Recruiting	`NCT04620954` - Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin	Phase 1/Phase 2
Completed	`NCT02312661` - Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer	Phase 1
Completed	`NCT01666444` - VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 2
Completed	`NCT01891344` - A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)	Phase 2